首页 > 多肽目录 > Enzyme Inhibitors / 酶抑制剂 (81) > Cyclohexylacetyl-Phe-Arg-Ser-Val-Gln-NH2

139P21

Cyclohexylacetyl-Phe-Arg-Ser-Val-Gln-NH2

Cyclohexylacetyl-Phe-Arg-Ser-Val-Gln-NH2

纯度:>95%HPLC
储存条价:-20°C,避光,干燥。

另提供从粗品至98%纯度规格,具体请联系我们! 本产品仅用于科学研究,不得用于人体!

产品详情

Cat#:
139P21
序列(三字母):
Cyclohexylacetyl-Phe-Arg-Ser-Val-Gln-NH2
序列(单字母):
Cyclohexylacetyl-FRSVQ-NH2
别名:
KKI-7
分子式:
C36H58N10O8
分子量:
758.92
CAS#:
113584-01-3
合成方法:
Synthetic
存储条件:
-20 °C,避光,干燥
应用:
Cardiovascular System & Diseases
产品描述:
Cyclohexylacetyl-Phe-Arg-Ser-Val-Gln-NH2别名KKI-7,是一个激肽释放酶(kallikrein)抑制剂,对人尿激肽释放酶(human urinary kallikrein), Ki = 4 μM,对人血浆激肽释放酶(human plasma kallikrein), Ki = 244 μM。KKI-7已被建议用作腺体激肽释放酶的体内抑制剂。
参考文献:
1.  Prolonged kallikrein inhibition does not affect the basal growth and secretory capacity of rat adrenal cortex, but enhances mineralo- and glucocorticoid response to ACTH and handling stress. Rebuffat P, Neri G, Bahçelioglu M, Malendowicz LK, Nussdorfer GG. Histol Histopathol. 2000 Apr;15(2):441-4. doi: 10.14670/HH-15.441. PubMed PMID: 10809362.
2.  The design of specific inhibitors of tissue kallikrein and their effect on the blood pressure of the rat. Burton J, Benetos A. Adv Exp Med Biol. 1989;247B:9-13. PubMed PMID: 2610106.
3.  In vivo inhibition of tissue kallikreins by kininogen sequence analogue peptides. Okunishi H, Spragg J, Burton J, Toda N. Adv Exp Med Biol. 1989;247B:23-8. PubMed PMID: 2481944.
4.  In vivo assay of specific kallikrein inhibitors. Okunishi H, Spragg J, Burton J. Agents Actions Suppl. 1987;22:381-90. PubMed PMID: 3481213.

订购流程

1)通过电话(+86-(0)-19961912513)邮件(sales@hongtide.com)联系我们;
2)提供合成多肽的具体需求,包括序列、质量和纯度,技术部门评估后给与报价。
3)签订多肽合成合同,交付合成预付款,科研机构先使用再付款!
4)合成过程定期跟您汇报合成进度及情况;
5)根据合同内容,随货提供发票;
6)如因本公司原因不能交货或合成失败,退还所有合成款!